Literature DB >> 6332120

Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.

B Ullman, D W Martin.   

Abstract

Purine nucleoside phosphorylase (PNP) deficiency in humans is associated with a severe T cell immunodeficiency. To understand further and exploit this T cell lymphospecificity, we have compared the cytotoxicities and metabolism of deoxyguanosine, the cytotoxic substrate of PNP and of arabinosylguanine, a deoxyguanosine analogue that is resistant to PNP cleavage, in T cell (8402) and B cell (8392) lines in continuous culture established from the same patient. In comparative growth rate experiments the T cells were 2.3-fold and 400-fold more sensitive to growth inhibition by deoxyguanosine and arabinosylguanine, respectively, than were the B cells. Only the T cells, but not the B cells, could phosphorylate in situ deoxyguanosine or arabinosylguanine to the corresponding triphosphate. Both the phosphorylation and cytotoxicity of arabinosylguanine in the T cell line could be prevented by deoxycytidine, which suggests that deoxycytidine-deoxyguanosine kinase initiated the intracellular metabolism and cytotoxicity of this nucleoside analogue. The sensitivity and selectivity of arabinosylguanine toward the T lymphoblastoid cells suggests a rational approach to the design of chemotherapeutic agents that are directed toward T cell malignancies and other T cell disorders.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332120      PMCID: PMC425252          DOI: 10.1172/JCI111514

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; A Cohen; D W Martin
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

3.  Deoxyguanosine toxicity in a mouse T lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction.

Authors:  L J Gudas; B Ullman; A Cohen; D W Martin
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

4.  Purine nucleoside phosphorylase from human erythrocytes. 3. Inhibition by the inosine analog formycin B of the isolated enzyme and of nucleoside metabolism in intact erythrocytes and sarcoma 180 cells.

Authors:  M R Sheen; B K Kim; R E Parks
Journal:  Mol Pharmacol       Date:  1968-05       Impact factor: 4.436

5.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.

Authors:  R P Agarwal; T Spector; R E Parks
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

6.  Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.

Authors:  I S Kazmers; B S Mitchell; P E Dadonna; L L Wotring; L B Townsend; W N Kelley
Journal:  Science       Date:  1981-12-04       Impact factor: 47.728

7.  Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency.

Authors:  A Cohen; L J Gudas; A J Ammann; G E Staal; D W Martin
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

8.  The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

Authors:  M R Grever; M F Siaw; W F Jacob; J A Neidhart; J S Miser; M S Coleman; J J Hutton; S P Balcerzak
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

9.  The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts.

Authors:  D A Carson; J Kaye; D B Wasson
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

View more
  6 in total

1.  Cloning and expression of human deoxyguanosine kinase cDNA.

Authors:  M Johansson; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Characterization of deoxyguanosine-resistant hypoxanthine-guanine phosphoribosyltransferase(-)metastatic variants altered in soybean-agglutinin-binding properties and cell-surface glycoproteins.

Authors:  J E Damen; M A Spearman; A H Greenberg; J A Wright
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells.

Authors:  I W Caras; D W Martin
Journal:  Mol Cell Biol       Date:  1988-07       Impact factor: 4.272

Review 4.  Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Tapan M Kadia; Varsha Gandhi
Journal:  Expert Rev Hematol       Date:  2016-12-08       Impact factor: 2.929

5.  Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Authors:  Kumudha Balakrishnan; Farhad Ravandi; Shanta Bantia; Anna Franklin; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-15

6.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Authors:  Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.